We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Prestige Consumer (PBH) Looks Well-Placed on Brand Strength
Read MoreHide Full Article
Prestige Consumer Healthcare Inc. (PBH - Free Report) appears in solid shape due to the strength of its brands and favorable demand. The company is also benefiting from a growing e-commerce channel. These upsides buoyed PBH’s first-quarter fiscal 2024 results, wherein the top and bottom lines beat the respective Zacks Consensus Estimate, and revenues increased year over year.
This Zacks Rank #2 (Buy) company offered encouraging guidance for fiscal 2024, which suggests top and bottom-line growth. The Zacks Consensus Estimate for the current fiscal-year earnings per share (EPS) has risen by a penny to $4.31 over the past 30 days.
Q1 Revenues & FY24 Guidance
Prestige Consumer’s total revenues grew 0.8% to $279.3 million in the first quarter of fiscal 2024 and beat the Zacks Consensus Estimate of $278 million. Excluding currency impacts, revenues jumped 7.8%. Revenues were backed by broad-based strength in North America.
Prestige Consumer’s performance reflects strength in its diversified portfolio, brand-building efforts and a focus on customer service. The company gained from growth in several categories like gastrointestinal and dermatological and remains well-positioned for fiscal 2024.
Management expects fiscal 2024 organic revenue growth of 1-2%. Revenues are anticipated in the range of $1,135-1,140 million in fiscal 2024 compared with the $1,127.7 million reported in fiscal 2023. Prestige Consumer envisions EPS in the range of $4.27-$4.32 in fiscal 2024. In fiscal 2023, the company posted a loss of $1.65 per share and an adjusted EPS of 4.21.
Prestige Consumer Healthcare Inc. Price, Consensus and EPS Surprise
Prestige Consumer prides itself on having a strong portfolio of healthcare brands. The company has made several lucrative acquisitions to boost its portfolio. It acquired TheraTears and four other over-the-counter consumer brands across the VMS and Cough & Cold categories from Akorn Operating Company LLC. This buyout was concluded in July 2021 and holds robust long-term prospects. This and products like Clear Eyes have solidified PBH’s footing in the eye care space.
The company has been making multi-year e-commerce investments for a while now. The e-commerce channel continued to experience solid growth in the first quarter of fiscal 2024 due to increased online shopping. PBH’s e-commerce operations have been benefiting from its efficient strategy of targeted marketing and content, effective product assortment and broad investments across e-commerce partners.
These upsides and efficient pricing actions place PBH well amid volatile currency fluctuations and elevated costs. Shares of the company have risen 1.2% in the past three months against the industry’s decline of 3.9%.
Other Promising Bets
Inter Parfums (IPAR - Free Report) , which manufactures, markets and distributes a range of fragrances and fragrance-related products, currently sports a Zacks Rank #1 (Strong Buy). IPAR has an expected EPS growth rate of 15% for three to five years. You can see the complete list of today’s Zacks #1 Rank stocks here
The Zacks Consensus Estimate for Inter Parfums’ current financial-year sales indicates 19.7% growth from the year-ago reported figure. IPAR has a trailing four-quarter earnings surprise of 45.9%, on average.
e.l.f. Beauty, Inc. (ELF - Free Report) , a cosmetic and skincare product company, currently carries a Zacks Rank #2. ELF has a trailing four-quarter earnings surprise of 108.3% on average.
The Zacks Consensus Estimate for e.l.f. Beauty’s current fiscal-year sales suggests growth of 41.2% from the corresponding year-ago reported figure. ELF’s expected EPS growth rate for three to five years is 21.7%.
Helen of Troy (HELE - Free Report) , a provider of several consumer products, currently has a Zacks Rank #2. HELE’s expected EPS growth rate for three to five years is 8%.
The Zacks Consensus Estimate for Helen of Troy’s current fiscal-year sales suggests a decline of 2.9% from the year-ago reported numbers. HELE has a trailing four-quarter earnings surprise of 8.1%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Prestige Consumer (PBH) Looks Well-Placed on Brand Strength
Prestige Consumer Healthcare Inc. (PBH - Free Report) appears in solid shape due to the strength of its brands and favorable demand. The company is also benefiting from a growing e-commerce channel. These upsides buoyed PBH’s first-quarter fiscal 2024 results, wherein the top and bottom lines beat the respective Zacks Consensus Estimate, and revenues increased year over year.
This Zacks Rank #2 (Buy) company offered encouraging guidance for fiscal 2024, which suggests top and bottom-line growth. The Zacks Consensus Estimate for the current fiscal-year earnings per share (EPS) has risen by a penny to $4.31 over the past 30 days.
Q1 Revenues & FY24 Guidance
Prestige Consumer’s total revenues grew 0.8% to $279.3 million in the first quarter of fiscal 2024 and beat the Zacks Consensus Estimate of $278 million. Excluding currency impacts, revenues jumped 7.8%. Revenues were backed by broad-based strength in North America.
Prestige Consumer’s performance reflects strength in its diversified portfolio, brand-building efforts and a focus on customer service. The company gained from growth in several categories like gastrointestinal and dermatological and remains well-positioned for fiscal 2024.
Management expects fiscal 2024 organic revenue growth of 1-2%. Revenues are anticipated in the range of $1,135-1,140 million in fiscal 2024 compared with the $1,127.7 million reported in fiscal 2023. Prestige Consumer envisions EPS in the range of $4.27-$4.32 in fiscal 2024. In fiscal 2023, the company posted a loss of $1.65 per share and an adjusted EPS of 4.21.
Prestige Consumer Healthcare Inc. Price, Consensus and EPS Surprise
Prestige Consumer Healthcare Inc. price-consensus-eps-surprise-chart | Prestige Consumer Healthcare Inc. Quote
Key Upsides
Prestige Consumer prides itself on having a strong portfolio of healthcare brands. The company has made several lucrative acquisitions to boost its portfolio. It acquired TheraTears and four other over-the-counter consumer brands across the VMS and Cough & Cold categories from Akorn Operating Company LLC. This buyout was concluded in July 2021 and holds robust long-term prospects. This and products like Clear Eyes have solidified PBH’s footing in the eye care space.
The company has been making multi-year e-commerce investments for a while now. The e-commerce channel continued to experience solid growth in the first quarter of fiscal 2024 due to increased online shopping. PBH’s e-commerce operations have been benefiting from its efficient strategy of targeted marketing and content, effective product assortment and broad investments across e-commerce partners.
These upsides and efficient pricing actions place PBH well amid volatile currency fluctuations and elevated costs. Shares of the company have risen 1.2% in the past three months against the industry’s decline of 3.9%.
Other Promising Bets
Inter Parfums (IPAR - Free Report) , which manufactures, markets and distributes a range of fragrances and fragrance-related products, currently sports a Zacks Rank #1 (Strong Buy). IPAR has an expected EPS growth rate of 15% for three to five years. You can see the complete list of today’s Zacks #1 Rank stocks here
The Zacks Consensus Estimate for Inter Parfums’ current financial-year sales indicates 19.7% growth from the year-ago reported figure. IPAR has a trailing four-quarter earnings surprise of 45.9%, on average.
e.l.f. Beauty, Inc. (ELF - Free Report) , a cosmetic and skincare product company, currently carries a Zacks Rank #2. ELF has a trailing four-quarter earnings surprise of 108.3% on average.
The Zacks Consensus Estimate for e.l.f. Beauty’s current fiscal-year sales suggests growth of 41.2% from the corresponding year-ago reported figure. ELF’s expected EPS growth rate for three to five years is 21.7%.
Helen of Troy (HELE - Free Report) , a provider of several consumer products, currently has a Zacks Rank #2. HELE’s expected EPS growth rate for three to five years is 8%.
The Zacks Consensus Estimate for Helen of Troy’s current fiscal-year sales suggests a decline of 2.9% from the year-ago reported numbers. HELE has a trailing four-quarter earnings surprise of 8.1%, on average.